Expertise

Our Investigators

Internationally recognized leaders in the field, PCCTC investigators come from the nation’s top academic medical centers where they are actively engaged in innovative, multidisciplinary prostate cancer research. Leveraging their unique insights into the underlying biology of the disease, our investigators developed the universally adopted clinical states model of prostate cancer and initiated one of the first efforts in oncology to prospectively validate endpoints proposed in definitive phase III trials, PCWG2. The individual research objectives of our investigators are well represented in our clinical trial portfolio and unified by our translational, team-based approach to drug and biomarker development.

Drug Development

The PCCTC selects and prioritizes clinical development opportunities based on our investigators’ unparalleled understanding of the global clinical trials landscape, the strength of the underlying science, and the potential to address critical unmet needs across prostate cancer’s clinical spectrum. Our studies are characterized by close interaction between basic scientists and clinical investigators to optimize the flow of promising agents into early-phase studies, and the complimentary development of novel trial designs, endpoints and predictive biomarkers which ensure the decision to advance or to discontinue a program is made objectively and rapidly. The PCCTC’s Management Team and Scientific Oversight Committee work together to address the scientific, legal, regulatory, database, budgetary, and management concerns of every trial to further accelerate the development of successful drug candidates.

Biomarker Development

A cornerstone of the PCCTC’s research strategy is the co-development of therapies and biomarkers. To transform the clinical management of prostate cancer in the near term, it is essential to develop drugs in more precisely defined and biologically relevant patient groups. The ability to screen for patients most likely to respond to a novel agent is essential for both shortening development timelines and reducing exposure to unnecessary toxicity from ineffective treatment. Following the FDA’s Critical Path Initiative, we initiated one of the first endeavors in oncology to define blood and imaging-based biomarkers, develop analytically valid assays for them, and subsequently design and conduct the dedicated clinical trials necessary to establish their clinical validity. Capitalizing on the intellectual synergy of our investigators, our extensive clinical trial portfolio, and our many resources and basic science collaborations, our long-term objective is to establish intermediate or surrogate endpoints which can predict clinical benefit and form the basis for accelerated drug approvals.

Recent News +++

Metacure Trial: Can We Cure More Oligometastatic Prostate Cancer?

Press Releases by Cleveland Clinic January 14, 2020

Study combines hormonal therapy with prostatectomy and radiation therapy of bone lesions

Learn More

Phase I DSTP3086S Trial Results Published

Media Relations by PCCTC November 11, 2019

PCCTC study demonstrates safety and antitumor activity of humanized immunoglobulin G1 anti...

Learn More

PCCTC Investigators Drs. Rathkopf and McBride Receive Prestigious SU2C Grant

Press Releases by PCCTC October 17, 2019

Award will fund novel trial using immunotherapy combined with radiation and hormone therap...

Learn More

PCCTC Germline Genetics Working Group Publishes Results

Press Releases by PCCTC July 29, 2019

Study published in Clinical Genitourinary Cancer argues multidisciplinary efforts are key ...

Learn More

PCCTC Working Group Publishes Genetic Testing Manuscript

Press Releases by PCCTC April 26, 2019

Investigators from the Prostate Cancer Clinical Trials Consortium (PCCTC) formed the Germl...

Learn More

Phase III DORA Study Now Enrolling Patients with mCRPC

Press Releases by PCCTC April 19, 2019

The phase III DORA study (ClinicalTrials.gov Identifier: NCT03574571) led by PCCTC investi...

Learn More
View More News +

Follow Us

RT @DoraTrial: @DoraTrial, an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in sub…
RT @IRONMANregistry: 🇪🇸 ¡Bienvenido @chpcastellon (PI: @Dav_Lorente), the latest site to open our International Registry to Improve Outcome…
Olaparib (Lynparza), a drug developed in early phase @ThePCCTC trials, granted priority FDA review for certain type… https://t.co/VPEroRQott

Join our team of dedicated clinical research professionals! The Prostate Cancer Clinical Trials Consortium is currently seeking a Quality Manager and Clinical Data Manager to help fulfill our…

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.